Department of Molecular and Cellular Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
J Mol Med (Berl). 2011 Sep;89(9):857-67. doi: 10.1007/s00109-011-0766-y. Epub 2011 May 19.
Cellular senescence, which can be induced by various stimuli, is a stress response that manifests as irreversible cell cycle arrest. Recent studies have revealed that cellular senescence can serve as a critical barrier for cancer development. Induction of cellular senescence by oncogenic insults, such as Ras overexpression or by inactivation of PTEN tumor suppressor, triggers an ARF/p53-dependent tumor-suppressive effect which can significantly restrict cancer progression. Given the important role of the ARF/p53 pathway in cellular senescence and tumor suppression, drugs that stabilize p53 expression have been developed and tested in clinical trials. However, a major hurdle for p53 targeting in cancer treatment arises from the frequent deficiency or mutation of ARF or p53 in human cancers, which, in turn, profoundly compromises their tumor-suppressive ability. Recent discoveries of novel regulators involved in ARF/p53-independent cellular senescence not only reveal novel paradigms for cellular senescence but also provide alternative approaches for cancer therapy.
细胞衰老,可由各种刺激诱导,是一种表现为不可逆细胞周期阻滞的应激反应。最近的研究表明,细胞衰老可以作为癌症发展的关键障碍。致癌刺激(如 Ras 过表达或抑癌基因 PTEN 的失活)诱导的细胞衰老,触发 ARF/p53 依赖性肿瘤抑制作用,可显著限制癌症进展。鉴于 ARF/p53 通路在细胞衰老和肿瘤抑制中的重要作用,已开发并在临床试验中测试了稳定 p53 表达的药物。然而,p53 靶向治疗在癌症治疗中面临的一个主要障碍是 ARF 或 p53 在人类癌症中经常缺失或突变,这反过来又严重削弱了它们的肿瘤抑制能力。最近发现的涉及 ARF/p53 非依赖性细胞衰老的新型调节因子,不仅揭示了细胞衰老的新范例,也为癌症治疗提供了替代方法。